BioSpace News Archive

Addus HomeCare Corporation, a provider of home care services, announced that it will release earnings for the second quarter ended June 30, 2021, on Monday, August 2, 2021, after the market close.

CureLab Oncology, a clinical-stage biotech company, has been granted a US patent for the application of its lead product for the treatment of ALS, Alzheimer’s, Huntington’s, and Parkinson’s disease.

Merck, known as MSD outside the United States and Canada, announced results from a Phase 2a clinical trial evaluating the safety, tolerability and pharmacokinetics of six monthly oral doses, over 24 weeks, of islatravir, the company’s investigational nucleoside reverse transcriptase translocation inhibitor, versus placebo for pre-exposure prophylaxis of HIV-1 infection in adults at low-risk of contracting HIV-1.

Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight to supply Opticyte® Amniotic Ophthalmic Repair Grafts to MIS-affiliated eye surgeons in three states.

Owens & Minor, Inc. plans to release financial results for the second quarter of 2021 on Tuesday, August 3, 2021, before trading begins on the New York Stock Exchange.

While many hospitalized patients with the coronavirus disease 2019 come to the hospital with symptoms of fever, cough or shortness of breath, a new large-scale study conducted by The Feinstein Institutes for Medical Research notes that older adults commonly present with atypical symptoms – like functional decline and altered mental status.

Loews Corporation will report second quarter 2021 financial results on Monday, August 2, 2021.

NeurOptics, the leader in the science of pupillometry, today announced its NPi® Pupillometer and the Neurological Pupil index™ (NPi®) are now being used by Inova Health System, Northern Virginia’s leading nonprofit healthcare provider, as an essential tool for measuring pupil reactivity in patients with brain injury.

ClexBio, a start-up developing bioengineered human blood vessels for transplant, has secured US$2.2m in seed funding from private investors and governmental grants.

Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX® (Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head and neck (SCCHN).